Mainstream

ResMed outlines 61%–63% gross margin target for FY26 while ramping up share buybacks and dividend

ResMed outlines 61%–63% gross margin target for FY26 while ramping up share buybacks and dividend

Post Contentrmd, rsmdfRead More

You might also be interested in reading CoinLoan Rolls Out Introductory Offer to Mark SOL Listing.

August 1, 2025
In Mainstream